

August 2026

WyoBlue Advantage is informing providers of upcoming changes for medical benefit drugs

New prior authorization requirements starting September 1, 2026

- Lumvoa (veligrotug-vvze), HCPCS code J3590
- Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), HCPCS code J3590

Prior authorization removal effective July 1, 2026

- Zinplava, HCPCS code J0565 (withdrawn from U.S. market by manufacturer)

HCPC code updates effective July 1, 2026

- Enoby/Xtrenbo (denosumab-qbde) Q5167
- Exdensur(depemokimab-ulaa) Q2361
- Itvisma (onasemnogene abeparvovec-brve) J3405
- Qivigy (human immune globulin) J1577
- Starjemza® IV (ustekinumab-hmny) Q5164
- Waskyra (etuvetidigene autotemcel) J3386
- Yartemlea (narsoplimab-wuug) J1289

Prior Authorization Submission Methods

Prior approval must be submitted through one of the following methods:

- Electronically: Use the Symphony Prior Authorization Portal, available within the Availity Essentials portal.
- Phone call: (844) 965-5080
- Paper form/Fax: Download the form from the WyoBlue Advantage website and fax it to (877) 369-3365.